The Effect Of Curcumin In The Recovery Of Severe Traumatic Brain Injury: A Double-blind Randomized Controlled Trial

Mohammadreza Saatian¹, Masoumeh Roustaei¹, Ebrahim Jalili^2*, Sara Ataei³, Ali Poormohammadi⁴, Maryam Farhadian⁵ and Ali Abdoli^1
*Correspondence: Ebrahim Jalili, Department of Emergency Medicine, Hamadan University of Medical Sciences, Iran,

Keywords

Trauma; Curcumin; Nano curcumin; Brain; Consciousness; Brain injury

Introduction

Traumatic Brain Injury (TBI) has affected approximately 50% of the world's population at some stage of life [1]. Trauma is one of the most important causes of death and disability in the active population in developing countries [2,3] and studies indicate that attention to trauma is less in these countries [4]. In 2016, 27.08 million new cases of brain trauma were registered in the world, which has increased the standardized prevalence of sense TBI in the world from 1990 to 2016 [5]. According to a report published by BMJ in 2017, TBI caused 8.1 million years of lost life in the world in 2016, which is a significant increase compared to the total number of years of life lost in 1990 [5].

Traumatic Brain Injury (TBI) is defined as an acquired brain disease caused by an external force in the form of mechanical, chemical, thermal, or electrical energy or a combination of these [6]. According to US statistics, 43% of severe TBI survivors are likely to suffer long term disability [7]. On the other hand, it should be noted that the burden of severe brain trauma extends to the patient's family and the health care system [8]. The direct and indirect economic and social costs caused by trauma to families are relatively high so the estimated cost of brain trauma is approximately 400 billion US dollars per year [9] and about 11% of the years of life lost due to disability. It is caused by trauma.

To date, there is no complete and effective treatment for traumatic brain injury, as most injuries occur due to secondary effects through various pathophysiological pathways [1]. In addition, the main approach in the treatment of brain trauma is measures such as damage control, surgery, and post-operative care [10]. In the control of damage caused by severe brain trauma, measures aimed at targeting multiple pathways are needed for more effective treatment of this disease. Previous studies have shown that several natural products and herbal medicines have been tested for their ability to improve disorders such as neuron inflammatory conditions characterized by impaired redox balance and excessive inflammation [11- 13].

There is evidence that curcumin can be traditionally used as a natural treatment for many diseases including diabetes, inflammatory diseases, and neurological disorders [14]. Some pharmacological studies also indicate the effect of curcumin in the treatment of brain trauma and injuries caused by it, but it seems that these results are not enough and more extensive research should be done in this field [1].

Curcumin is considered a poly phenolic that, in addition to its antiinflammatory, thrombolytic and anti-cancer effects, can be used in the treatment of several diseases such as Alzheimer's disease and injuries caused by trauma by inhibiting the accumulation of amyloid prot ein [15].

The effect of curcumin on endogenous neuron regeneration in rats after TBI has been confirmed, so the apoptotic cells in the damaged area of rats that had TBI and received curcumin were significantly less than in the control group [16]. In addition to the animal studies that have shown curcumin's therapeutic effect on brain trauma, they have not shown any toxicity at a dose of 500 mg [17]. On the other hand, the anti-inflammatory effect of curcumin with low molecular weight has been of interest for centuries [18], despite various studies on curcumin in laboratory animals and the lack of studies on humans considering the published literature, this study is aimed to the effect of curcumin in the treatment of severe brain injuries in patients.

Methods

The current study is a controlled double blind clinical trial study that was conducted on 128 patients (Figure 1). In this study, the patients were divided into two control groups by a simple randomization method (recipients of Standard care treatment i.e. treatment according to Yeoman's treatment protocol and treatment with prophylactic anticonvulsant drugs and antibiotics if needed and placebo) and intervention group (i.e. recipients of Standard care treatment and oral Nanocurcumin as orally or through a nasogastric tube in the amount of 500 mg every 8 hours and for 3 weeks). In this study, patients suffering from severe brain trauma referred to the special care department of neurosurgery and specialized and sub-specialized in Hamadan Besat hospital, West Iran from 2019 to 2021 were selected.

The included patients were randomized using a computer random number generator to select random permuted blocks with a block size of 8 and an equal allocation ratio. Sequentially numbered, opaque, sealed envelopes were used to ensure concealment. Three members of the study team recruited, enrolled, and assigned participants to a computer‐generated randomization sequence, held by an independent observer.

Inclusion criteria were people between the ages of 18 and 70 years, duration of concussion less than 24 hours, level of consciousness (GCS) 8 or less, not candidates for craniotomy surgery, and pregnant and lactating women.

The exclusion criteria were those who had an unstable systemic condition, the presence of multiple and severe organic injuries, lack of brain stem reflexes, kidney failure, and the need for any type of surgery in the early days of hospitalization.

If a complication occurs and is observed by the attending physician, the treatment with curcumin was stopped. The patients in both groups were subjected to mechanical ventilation if needed, and no patient received barbiturate treatment. Consciousness level, blood pressure, the reaction of pupils to light, movement, and strength of organs were checked daily. Brain CT scan was performed on the 1^st, 3^rd, and 7^th days based on the patient's condition. To investigate drug side effects, parameters such as serum biochemistry, platelet count, hemoglobin, PT, PTT, serum electrolytes, and liver tests were measured on the 1^st, 3^rd, and 7^th days after hospitalization. To classify patients at discharge, GOS was used in 3 month and 6 month follow ups. Patients with good recovery or moderate disability were included in the favorable outcome group, and those with severe disability or vegetative life, as well as those who died, were included in the unfavorable outcome group.

This study was approved and registered by the Research Ethics Committee of the Hamadan University of Medical Sciences at the address IR.UMSHA. REC.1398.010 and the IRCT code is IRCT20120215009014N305.

Informed consent was obtained from all participants in this study. Participants' privacy and data confidentiality were guaranteed.

Analysis

We used an intention‐to‐treat analysis approach and include all randomly assigned participants. In this study, mean and standard deviation were used to describe quantitative variables, and number and percentage were used to describe qualitative variables. To compare the level of alertness and biochemical factors of patients in two groups of control and intervention from the variance analysis of repeated data, to determine the relationship between the performance of patients after discharge in the two groups using the chi-square test, to compare the frequency of edema in the two groups using the exact-Fisher test. The significance level in this study is less than 0.05 and SPSS version 21 software was used.

Results

This study was conducted on 128 severe brain trauma patients who were randomized into two intervention and control groups. The number of men in the intervention and control groups was 51 (79.7%) and 49 (76.7%) respectively. The Chi-square test showed that the gender distribution between the two groups was not statistically significant (p=0.669). Patients in the intervention (14.44 ± 31.86) and control (33.34 ± 14.86) groups did not differ in terms of age (p=0.543). The frequency of the cause of severe brain trauma among patients is shown in Table 1. Although Table 1 shows that the performance 6 months after discharge based on the GOS score was not significantly different between the two intervention and control groups, the frequency of optimal performance in the 3^rd month after discharge in the intervention group was significantly higher than in the control group (p=0.034). Brain CT scan findings on the 1^st and 3^rd day showed no difference in terms of edema between the two groups, but on the 7^th day, a score of 1 in the intervention group and a score of 3 in the control group were significantly observed p=0.038 (Table 1).

The findings of the present study showed that although there was no significant difference in the level of consciousness of patients in the two groups on the 1^st day of hospitalization, the level of consciousness of patients in the intervention group was significantly higher than the control group on the 3^rd (p=0.004) and 7^th (p=0.001) days.

Also, the analysis of the variance of the repeated data showed that the changes in the level of consciousness of the patients in the intervention group were significantly different from the control group, p=0.003 (Table 2).

According to the findings in Table 2, there was a significant difference in the PT values of patients in the intervention and control groups on the 1^st (p<0.001), 3^rd (p=0.002), and 7^th (p<0.001) days of hospitalization. The comparison of PT sizes in two groups showed that this parameter is different between the two groups over time (p=0.021) and the PT of patients in the intervention group is always lower than the control group.

In addition, there is no statistically significant difference in the PTT value between the patients of the two groups. The average INR in the intervention group was lower than the control group in all three stages, i.e. the 1^st, 3^rd, and 7^th days of hospitalization. Variance analysis of repeated data also showed that there is a significant difference between these averages during the measurements made in the two groups, p=0.023 (Table 2). The biggest difference in INR between the two groups was observed on the seventh day of hospitalization.

During the follow up of the patients, there is a significant difference in sodium changes between the intervention and control groups (p=0.007), so the biggest difference was observed on the third day of follow up (p=0.019) between the two groups. According to the results of Table 2, no significant difference was observed in the changes in blood urea and creatinine between the two groups. The results of this study showed that although there is no difference in the general trend of urea changes between the patients of the intervention and control groups, that is, they had almost a slight increase (p=0.660), but in the two by two comparison of the groups on the 1^st day (p=0.009) and the 7^th day (p=0.015) statistically significant difference was evident.

According to the findings, there was no difference between the creatinine levels of the patients in the two groups (p=0.073), while the average white blood cell count was significantly lower in the patients of the intervention group (p=0.016). The findings show that the difference between the white blood cells between the two groups was on the 3^rd day (p=0.004) and the 7^th day (p=0.009). The average SGOT of patients in the intervention group was about 1.6 times higher than the control group, and this difference was significant (p=0.024). However, there was no difference between the SGOT of control and intervention group patients on the first and third days. In addition, the variance analysis of repeated data also did not show a significant difference between the two groups in terms of SGOT changes in general (0.313). In both intervention and control groups, there was no significant difference between the average SGPT (p=0.600) and ALK (p=0.203) during the hospitalization period of the patients.

This study showed that the rate of blood pressure reduction (p=0.028) and death (p<0.001) was significantly lower in patients who received routine+curcumin treatment compared to the control (Table 3). Pupil reactions of the right and left eyes were checked on the seventh day of hospitalization in both groups and no difference was observed between the two groups.

Discussion

In the current study, considering the beneficial properties of curcumin in relieving inflammation [14], it was used to treat severe brain trauma patients in comparison to routine treatment in a clinical trial study. We focused on curcumin because it is a spice with multiple pharmacological properties, very low toxicity, and availability.

Cerebral edema and subsequent increase in ICP as well as decreased level of consciousness are serious complications of brain trauma that contribute to increased patient mortality and long term disability [18]. The present study clearly shows that doses of 500 mg every 8 hours of nano curcumin reduce cerebral edema and its mortality, especially from the 7^th day onwards, reducing the frequency of hypotension, and the level of cerebral function in the first trimester. And secondly, it improves post-discharge, which improper performance can cause death, and improves some biochemical fact ors.

The therapeutic properties of curcumin in the intervention group reduced the amount of brain edema caused by severe brain trauma compared to the control group. Such a result with the study of Samini et al. [19] which was conducted on rats with traumatic brain injury with doses of 50 mg/ kg and 100 mg/kg and also with the results of the study of Laird MD et al. [18] with three doses of 150 mg/kg-300 mg/kg was done. Siahaan et al.'s study [20] on rats with mild brain damage reported that the use of turmeric extract is not effective in improving neurological function caused by repeated mild brain damage in rats. It should be noted that the present study was conducted on humans and the maximum dose was 10 mg/kg. The difference between the results of this study and siahaan may be due to the severity of the trauma.

One of the results of this study was a significant increase in the level of consciousness of patients receiving curcumin compared to the control on the third day of treatment and at the time of discharge. Such a result is not far from expected, because Smal et al. [21] conducted a clinical trial study and confirmed the effect of curcumin bioavailability on memory and brain amyloid over 18 months. Previous studies emphasized that curcumin can relieve inflammation and apoptosis by modulating the involved molecular signaling pathways [22]. On the other hand, Shu et al. [16] also showed that curcumin is effective on endogenous neuron regeneration in an animal model after brain trauma. Therefore, the chemical mechanisms at the level of the brain also confirm the results of this study.

Another important result of this study was a reduction in the death rate among curcumin recipients compared to controls. This result is also reasonable because Ahmadi et al. [23] showed in a clinical trial that curcumin as an adjunctive treatment with riluzole can increase the survival of patients with amyotrophic lateral sclerosis. They reported this significant difference with the Kaplan-Meier survival plot. Although the present study was conducted on patients with severe brain trauma, both our study and Ahmadi et al.'s study confirmed the effect of curcumin on patients' survival.

Another important result we achieved in this study was that we did not observe any difference between severe brain trauma patients who received curcumin and controls in terms of coagulation factors, electrolytes, liver enzymes, and kidney function. This means that there is no additional risk of liver, coagulation, and electrolyte damage in patients taking curcumin. Regarding the safety of curcumin as a treatment or complementary treatment in other diseases, reports have been published [24,25], and in this study, it was also confirmed that it is without complications in severe brain trauma patients. In this study, we used a dose of 500 mg of curcumin per day, while some studies used doses of 1200 mg per day and did not report any toxicity [23,24]. Zhu et al. [26] during their study confirmed that curcumin as a phytochemical compound with anti-inflammatory properties reduces inflammation and accelerates the recovery of brain funct ion.

Conclusion

This study showed that the administration of oral Nanocurcumin supplement at the rate of 500 mg every 8 hours in a 3 week treatment period in hospitalized patients with severe brain trauma can have an effective role in improving cerebral edema and increasing the level of consciousness of patients in addition to their routine treatment. and this is without any side effects such as disorders in the coagulation, liver, and kidney systems also it did not any interactions with other drugs drug.

Acknowledgments

The authors would like to thank the Clinical Research Development Unit (CRDU) of Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran for their support cooperation and assistance thought the period of study. (Grant number 14001203310086).

Conflict of Interest Statement

This study showed that the administration of oral Nanocurcumin supplement at the rate of 500 mg every 8 hours in a 3 week treatment period in hospitalized patients with severe brain trauma can have an effective role in improving cerebral edema and increasing the level of consciousness of patients in addition to their routine treatment. and this is without any side effects such as disorders in the coagulation, liver, and kidney systems also it did not any interactions with other drugs drug.

Acknowledgments

The authors would like to thank the Clinical Research Development Unit (CRDU) of Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran for their support cooperation and assistance thought the period of study. (Grant number 14001203310086).

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

Funding

The Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences funded this study (Grant number 14001203310086). However, the funder had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.

References

1. Sahebkar, A, Sathyapalan T, Guest PC and Barreto GE. “Identification of Difluorinated Curcumin Molecular Targets Linked to Traumatic Brain Injury Pathophysiology.” Biomed Pharmacother 148(2022):112770.

   [Crossref] [Google Scholar]

2. Naghavi, M, Shahraz S, Sepanlou S and BESc P, et al. “Health Transition in Iran toward Chronic Diseases based on Results of Global Burden of Disease 2010.” Arch Iran Med 17(2014):321-335.

   [Google Scholar] [Pubmed]

3. Rowell, S, Barbosa R, Diggs B and Schreiber M, et al. “Specific Abbreviated Injury Scale Values are Responsible for the Underestimation of Mortality in Penetrating Trauma Patients by the Injury Severity Score.” J Trauma Acute Care Surg 71(2011):S384-S8.

   [Crossref] [Google Scholar]

4. London, J, Mock C, Quansah R and Abantanga F, et al. “Priorities for Improving Hospital-Based Trauma Care in an African City.” J Trauma Acute Care Surg 51(2001):747-753.

   [Crossref] [Google Scholar]

5. James, SL, Castle CD, Dingels ZV and Fox JT, et al. “Estimating Global Injuries Morbidity and Mortality: Methods and Data used in the Global Burden of Disease 2017 study.” Inj Prev 26(2020):i125–i53.

   [Crossref] [Google Scholar]

6. Capizzi, A, Woo J and Verduzco GM. “Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management.” Med Clin N Am 104(2020):213.

   [Crossref] [Google Scholar]

7. Hackenberg, K and Unterberg A. “Traumatic Brain Injury.” Der Nervenarzt 87(2016):203-216.

   [Crossref] [Google Scholar]

8. Kanmani, T, Thimmappur R, Birudu R and Reddy NK, et al. “Burden and Psychological Distress of Intensive Care Unit Caregivers of Traumatic Brain Injury Patients.” Indian J Crit Care Med 23(2019):220-223.

   [Crossref] [Google Scholar]

9. Ashrafizadeh, M, Mohammadinejad R, Farkhondeh T and Samarghandian S. “Curcumin Activates the Nrf2 Pathway and Induces Cellular Protection against Oxidative Injury.” Curr Mol Med 20(2020):116-133.

   [Crossref] [Google Scholar]

10. Rubiano, A, Maldonado M, Montenegro J and Restrepo C, et al. “The Evolving Concept of Damage Control in Neurotrauma: Application of Military Protocols in Civilian Settings with Limited Resources.” World Neurosurg 125(2019):e82–e93.

    [Crossref] [Google Scholar]

11. Maurya, S, Bhattacharya M, Mishra S and Bhattacharya A, et al. “Microglia Specific Drug Targeting using Natural Products for the Regulation of Redox Imbalance in Neurodegeneration.” Front Pharmacol 12(2021):654489.

    [Crossref] [Google Scholar]

12. Yousefsani, B, Barreto G and Sahebkar E. “Beneficial Medicinal Plants for Memory and Cognitive Functions based on Traditional Persian medicine.” Adv Exp Med Biol 1308(2021):283–90.

    [Crossref] [Google Scholar]

13. Mazo, N, Echeverria V, Cabezas R and Avila-Rodriguez M, et al. “Medicinal Plants as Protective Strategies against Parkinson’s Disease.” Curr Pharmaceut Des 23(2017):4180–4188.

    [Crossref] [Google Scholar]

14. Bagheri, H, Ghasemi F, Barreto G and Rafiee R, et al. “Effects of Curcumin on Mitochondria in Neurodegenerative Diseases.” Biofactors 46(2020):5-20.

    [Crossref] [Google Scholar]

15. Siahaan, AMP and Japardi I. “Supplementation of Turmeric Extract Does Not Improve Neurological Function Following Repetitive Mild Traumatic Brain Injury in the Rat Open Access.” Maced J Med Sci 6(2018):1953–1958.

    [Crossref] [Google Scholar]

16. Shu, Y, Wang T, Tang X and Pan C. “The Effect of Curcumin on Endogenous Neuron Regeneration in Rats after TBI.” Revista Argentina de Clínica Psicológica.” 29(2020):864.

    [Crossref] [Google Scholar]

17. Lao, C, Ruffin M, Normolle D and Heath D, et al. “Dose Escalation of a Curcuminoid Formulation.” BMC Complement Altern Med 6(2006):1-4.

    [Crossref] [Google Scholar]

18. Laird, MD, Sangeetha S, Swift AEB and Meiler SE, et al. “Does Curcumin Attenuate Cerebral Edema following Traumatic Brain Injury in Mice: A Possible Role for Aquaporin-4?” J Neurochem 113(2010):6.

    [Crossref] [Google Scholar]

19. Samini, F, Samarghandian S, Borji A and Mohammadi G. “Curcumin Pretreatment Attenuates Brain Lesion Size and Improves Neurological Function Following Traumatic Brain Injury in the Rat.” Pharmacol Biochem Behav 110(2013):238-244.

    [Crossref] [Google Scholar]

20. Siahaan, AMP and Japardi I. “Supplementation of Turmeric Extract does not Improve Neurological Function Following Repetitive Mild Traumatic Brain Injury in the Rat.” Intern Conf Sci, Techn, Eng, Env and Ram Researches 1(2018):486-490.

    [Crossref] [Google Scholar]

21. Small, G, Siddarth P, Li Z and Miller K, et al. “Memory, and Brain Amyloid and Tau Effects of a Bioavailable form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial.” Am J Geriatr Psychiatry 26(2018):266-77.

    [Crossref] [Google Scholar]

22. Farkhondeh, T, Samarghandian S, Roshanravan B and Peivasteh-Roudsari L. “Impact of Curcumin on Traumatic Brain Injury and Involved Molecular Signaling Pathways.” Recent Pat Food Nutr Amp Agric 11(2020):137-44.

    [Crossref] [Google Scholar]

23. Ahmadi, M, Agah E, Nafissi S and Jaafari M, et al. “Safety and Efficacy of Nano Curcumin as Add-on Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial.” Neurotherapeutics 15(2018):430-438.

    [Crossref] [Google Scholar]

24. Lao, C, Ruffin M, Normolle D and Heath D, et al. “Dose Escalation of a Curcuminoid Formulation. BMC complementary and alternative medicine.” BMC Complement Altern Med 6(2006):1-4.

    [Crossref] [Google Scholar]

25. Shokri, MN, Bagherniya M, Askari G and Sathyapalan T, et al. “Studies on Biomarkers and New Targets in Aging Research in Iran: A Systematic Review of the Clinical Use of Curcumin for the Treatment of Osteoarthritis.” Springer Cham 5(2021):265–282.

    [Crossref] [Google Scholar]

26. Zhu, Ht, Bian C, Yuan Jc and Chu Wh, et al. “Curcumin Attenuates Acute Inflammatory Injury by Inhibiting the TLR4/MyD88/NF-κB Signaling Pathway in Experimental Traumatic Brain Injury.” J Neuroinflammation 27(2014):1742-2094.

    [Crossref] [Google Scholar]